Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) CFO Sells 4,160 Shares of Stock

by · The Cerbat Gem

Twist Bioscience Co. (NASDAQ:TWST – Get Free Report) CFO Adam Laponis sold 4,160 shares of the firm’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total value of $185,536.00. Following the completion of the sale, the chief financial officer now directly owns 89,237 shares of the company’s stock, valued at $3,979,970.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Adam Laponis also recently made the following trade(s):

  • On Wednesday, October 9th, Adam Laponis sold 856 shares of Twist Bioscience stock. The shares were sold at an average price of $41.81, for a total transaction of $35,789.36.

Twist Bioscience Trading Down 0.3 %

TWST opened at $45.40 on Monday. The stock’s 50-day moving average price is $43.69 and its 200 day moving average price is $45.74. Twist Bioscience Co. has a 12-month low of $15.85 and a 12-month high of $60.90. The firm has a market cap of $2.66 billion, a price-to-earnings ratio of -11.88 and a beta of 1.78.

Institutional Trading of Twist Bioscience

Several hedge funds have recently made changes to their positions in the business. Signaturefd LLC increased its stake in Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after buying an additional 306 shares during the period. EdgeRock Capital LLC purchased a new stake in shares of Twist Bioscience during the second quarter worth $43,000. Blue Trust Inc. raised its stake in shares of Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after acquiring an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new position in Twist Bioscience in the second quarter valued at $61,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after purchasing an additional 381 shares during the period.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Barclays reduced their target price on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. Robert W. Baird upped their price objective on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, August 5th. JPMorgan Chase & Co. raised their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Leerink Partners increased their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. Finally, Evercore ISI boosted their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $51.22.

Check Out Our Latest Stock Analysis on Twist Bioscience

About Twist Bioscience

(Get Free Report)

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Featured Articles